Report overview
This report contains market size and forecasts of Ulcerative Colitis Immunology Drugs in global, including the following market information:
Global Ulcerative Colitis Immunology Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ulcerative Colitis Immunology Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Ulcerative Colitis Immunology Drugs companies in 2021 (%)
The global Ulcerative Colitis Immunology Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Adalimumab Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ulcerative Colitis Immunology Drugs include Janssen Biotech, Inc., Bristol-Myers Squibb Company, AbbVie Inc., UCBCares, AMGEN, Celltrion Healthcare, Biogen, Genentech USA, Inc. and ROCHE and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Ulcerative Colitis Immunology Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ulcerative Colitis Immunology Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Ulcerative Colitis Immunology Drugs Market Segment Percentages, by Type, 2021 (%)
Adalimumab
Certolizumab Pegol
Tofacitinib
Etanercept
Golimumab
Abatacept
Infliximab
Others
Global Ulcerative Colitis Immunology Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Ulcerative Colitis Immunology Drugs Market Segment Percentages, by Application, 2021 (%)
Rheumatoid Arthritis
Crohn's Disease(CD)
Ankylosing Spondylitis(AS)
Psoriasis(Ps)
Ulcerative Colitis(UC)
Global Ulcerative Colitis Immunology Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Ulcerative Colitis Immunology Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ulcerative Colitis Immunology Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ulcerative Colitis Immunology Drugs revenues share in global market, 2021 (%)
Key companies Ulcerative Colitis Immunology Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Ulcerative Colitis Immunology Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Janssen Biotech, Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
UCBCares
AMGEN
Celltrion Healthcare
Biogen
Genentech USA, Inc.
ROCHE
Pfizer Inc.
